BioSpace News Archive

Immunovia invites you to a teleconference for all stakeholders and media on Wednesday, May 13, 2020 at 16:30 CET.

Despite early reports suggesting rare disease in children, latest research shows considerable numbers of hospitalized and critically ill pediatric patients

Genova Diagnostics has introduced a COVID-19 test under the FDA Emergency Use Authorization (EUA).

Shockwave Medical, Inc., a pioneer in the development and commercialization of Intravascular Lithotripsy to treat complex calcified cardiovascular disease, reported financial results for the three months ended March 31, 2020.

Osmotica Pharmaceuticals plc, a fully integrated biopharmaceutical company, announced business highlights and financial results for the three months ended March 31, 2020.

ClearPoint Neuro, Inc. announced financial results for its first fiscal quarter ended March 31, 2020.

TELA Bio, Inc., a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, reported financial results for the first quarter ended March 31, 2020.

Adaptive Biotechnologies Corporation, a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, reported financial results for the quarter ended March 31, 2020.

Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, reported its financial results for the first quarter ended March 31, 2020.

Axonics Modulation Technologies, Inc. announced the closing of its public offering of 4,600,000 shares of common stock at the public offering price of $32.50 per share, which includes the shares purchased pursuant to the exercise in full of the underwriters’ option to purchase up to an additional 600,000 shares of its common stock.